IPM Take
Radioligand therapy keeps producing serious evidence, but health systems still treat it like a specialist niche. COMPETE adds head-to-head Phase III data in advanced GEP-NETs. Now policymakers need to stop admiring the science from a distance and build the delivery architecture.
Executive Summary
ITM announced that the primary analysis of the Phase III COMPETE trial was published in The Lancet. The trial compared non-carrier-added ¹⁷⁷Lu-edotreotide with everolimus in 309 patients with advanced, progressive, Grade 1 or Grade 2 somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours across 49 global sites. Median progression-free survival was 23.9 months with ¹⁷⁷Lu-edotreotide versus 14.1 months with everolimus. Objective response rate was 22% versus 4%, and grade 3/4 treatment-related adverse events were 18% versus 40%.
Why it matters
- Patients / advocates: For advanced GEP-NETs, longer disease control can mean meaningful time, but only if treatment centres are reachable.
- Clinicians: COMPETE gives head-to-head evidence against an active systemic comparator, not just another single-arm signal.
- Hospitals / providers: Radioligand therapy requires nuclear medicine infrastructure, radiation safety, trained teams and reliable scheduling.
- Policymakers / HTA bodies: Reimbursement must account for the whole pathway, including diagnostics, isotope logistics and treatment capacity.
Radioligand therapy does not fail because the science is boring. It fails when the system around it is too small.
The COMPETE trial gives the field another serious piece of evidence. In advanced, progressive, SSTR-positive GEP-NETs, investigational ¹⁷⁷Lu-edotreotide improved median progression-free survival versus everolimus: 23.9 months compared with 14.1 months. The objective response rate was also higher, 22% versus 4%. Grade 3/4 treatment-related adverse events were reported less often with ¹⁷⁷Lu-edotreotide than with everolimus.
This matters because GEP-NETs are not high-volume headline cancers, and because radioligand therapy has too often been discussed as a technical specialty rather than a system challenge.
The drug is only one part of the story. The patient needs somatostatin receptor imaging. The centre needs nuclear medicine capacity. The system needs isotope supply, trained staff, radiation-safety procedures, multidisciplinary referral and reimbursement that does not treat every operational component as someone else’s problem.
That is the trap for radioligand therapy. Everyone likes the elegance of targeting. Fewer institutions want to pay for the infrastructure that makes targeting possible.
COMPETE also matters because it was not simply a comparison against nothing. It tested ¹⁷⁷Lu-edotreotide against everolimus, a recognised systemic option. That helps close an evidence gap in a field where prospective head-to-head data are limited.
But publication is not implementation. ITM-11 remains investigational and under regulatory review. If it reaches approval, countries will still need to decide where treatment is delivered, how patients are referred, how isotope logistics are protected and how smaller centres connect into larger networks.
Radioligand therapy is building its evidence base. Health systems now need to build the muscle.
